The study suggests that employing both EGFR and ALK inhibitors might be a promising therapeutic approach for managing NSCLC marked by simultaneous EGFR mutation and EML4-ALK rearrangement [73,74]. This evidence concerns the gene EML4 and non-small cell lung carcinoma.